FDA Warns Baxter On Hemophilia Drug Promotion

Law360, New York (July 31, 2008, 12:00 AM EDT) -- The U.S. Food and Drug Administration has warned Baxter Healthcare Corp. over a promotion of one of its hemophilia drugs that the agency says overstates the coagulant's safety and efficacy.

The company's "clinical thank you e-mail" misbrands FEIBA VH — a drug containing freeze-dried sterile human plasma that helps to limit spontaneous or surgical bleeding in patents with hemophilia — and violates the U.S. Food, Drug and Cosmetic Act, according to a letter posted to the agency's Web site Wednesday.

"By promoting misleading safety and efficacy...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.